Carbidopa / levodopa Alternatives Compared
| Carbidopa / levodopa | Sinemet (carbidopa / levodopa) | Amantadine |
|
|---|
| Carbidopa / levodopa | Sinemet (carbidopa / levodopa) | Amantadine |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Carbidopa/levodopa is a medication that may be used for the treatment of Parkinson's disease. Available as immediate-release tablets, extended-release tablets, and extended-release capsules... View more |
Prescription only
Sinemet is a medication that may be used for the treatment of Parkinson's disease that is available in three different strengths: Sinemet 25/100, Sinemet 25/250, and Sinemet 10/100. Dyskinesias... View more |
Prescription only
Amantadine may be used to treat dyskinesia or reduce the number of OFF episodes in those with Parkinson's disease (PD) OR in the treatment or prevention of Influenza A viral infection. Nausea... View more |
Related suggestions Parkinson's Disease
Popular comparisons
|
|||||||||||||||||||||||
| More about Carbidopa / levodopa | More about Sinemet (carbidopa / levodopa) | More about Amantadine | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Carbidopa / levodopa has an average rating of 7.2 out of 10 from a total of 94 ratings on Drugs.com. 64% of reviewers reported a positive effect, while 20% reported a negative effect. |
Sinemet has an average rating of 7.7 out of 10 from a total of 30 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 10% reported a negative effect. |
Amantadine has an average rating of 6.9 out of 10 from a total of 54 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 20% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Carbidopa / levodopa side effects |
View all Sinemet side effects |
View all Amantadine side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
Lower cost generic |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Carbidopa / levodopa prices |
View all Sinemet prices |
View all Amantadine prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Atamet, Crexont, Dhivy, Duopa, Parcopa, Rytary, Sinemet | Other carbidopa / levodopa brands include: Atamet, Crexont, Dhivy, Duopa, Parcopa, Rytary | Gocovri, Osmolex ER | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
2.3 hours |
2.3 hours |
19 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 520 drugs are known to interact with Carbidopa / levodopa:
|
A total of 520 drugs are known to interact with Sinemet:
|
A total of 131 drugs are known to interact with Amantadine:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
May 02, 1975 |
May 02, 1975 |
February 14, 1968 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.